Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
US$ billions, as reported in each year's annual results.
Revenue of the fiscal year. US dollars at each year's exchange rate.
| Measure | Pfizer Inc.✕ PFE · #126 in the world | Samumed✕ |
|---|---|---|
| Profile | ||
| Country | 🇺🇸 USA | 🇺🇸 USA |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceutical | — |
| Founded | 1849 | 2008 |
| Size | ||
| Market cap | $170.7 B | — |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | Pfizer Inc. | Samumed |
|---|---|---|
| 2025 | $62.6 BSEC | — |
| 2024 | $63.6 BSEC | — |
| 2023 | $59.6 BSEC | — |
| 2022 | $101.2 BSEC | — |
| 2021 | $81.3 BSEC | — |
| 2020 | $41.7 BSEC | — |
| 2019 | $40.9 BSEC | — |
| 2018 | $40.8 BSEC | — |
| 2017 | $52.5 BSEC | — |
| 2016 | $52.8 BSEC | — |
| 2015 | $48.9 BSEC | — |
| 2014 | $49.6 BSEC | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| Revenue | $62.6 B | — |
|---|
| Net income | $7.8 B | — |
|---|
| Employees | 75,000 | — |
|---|
| Valuation | ||
|---|---|---|
| P/E ratio | 42.3× | — |
| Price to sales | 2.7× | — |
| Price to book | 2.0× | — |
| Free cash flow yield | 5.3% | — |
| Profitability | ||
|---|---|---|
| Gross margin | 74.3% | — |
| Net margin | 12.4% | — |
| Return on equity | 8.9% | — |
| Growth | ||
|---|---|---|
| Revenue growth | -1.6% | — |
| Revenue growth, 3 years a year | -14.8% | — |
| Earnings per share growth | -3.5% | — |
| Financial strength | ||
|---|---|---|
| Debt to equity | 0.7× | — |
| Cash | ||
|---|---|---|
| Free cash flow margin | 14.5% | — |
| Strength scores | ||
|---|---|---|
| Piotroski F-score | 5 of 9 | — |
| Altman Z-score zone | — | — |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 | Market cap — |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.